<SEC-DOCUMENT>0001777813-20-000006.txt : 20200515
<SEC-HEADER>0001777813-20-000006.hdr.sgml : 20200515
<ACCEPTANCE-DATETIME>20200515160920
ACCESSION NUMBER:		0001777813-20-000006
CONFORMED SUBMISSION TYPE:	13F-HR
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200515
DATE AS OF CHANGE:		20200515
EFFECTIVENESS DATE:		20200515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Palo Alto Investors LP
		CENTRAL INDEX KEY:			0001306923
		IRS NUMBER:				770558164
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		13F-HR
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	028-11013
		FILM NUMBER:		20885185

	BUSINESS ADDRESS:	
		STREET 1:		470 UNIVERSITY AVE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
		BUSINESS PHONE:		650-325-0772

	MAIL ADDRESS:	
		STREET 1:		470 UNIVERSITY AVE
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Palo Alto Investors, LLC
		DATE OF NAME CHANGE:	20041025
</SEC-HEADER>
<DOCUMENT>
<TYPE>13F-HR
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/thirteenffiler" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>13F-HR</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <flags>
        <confirmingCopyFlag>false</confirmingCopyFlag>
        <returnCopyFlag>false</returnCopyFlag>
        <overrideInternetFlag>false</overrideInternetFlag>
      </flags>
      <filer>
        <credentials>
          <cik>0001306923</cik>
          <ccc>XXXXXXXX</ccc>
        </credentials>
      </filer>
      <periodOfReport>03-31-2020</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <reportCalendarOrQuarter>03-31-2020</reportCalendarOrQuarter>
      <filingManager>
        <name>Palo Alto Investors LP</name>
        <address>
          <com:street1>470 UNIVERSITY AVE</com:street1>
          <com:city>PALO ALTO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94301</com:zipCode>
        </address>
      </filingManager>
      <reportType>13F HOLDINGS REPORT</reportType>
      <form13FFileNumber>028-11013</form13FFileNumber>
      <provideInfoForInstruction5>N</provideInfoForInstruction5>
    </coverPage>
    <signatureBlock>
      <name>Angela Nguyen-Dinh</name>
      <title>Chief Compliance Officer</title>
      <phone>(650) 325-0772</phone>
      <signature>Angela Nguyen-Dinh</signature>
      <city>Palo Alto</city>
      <stateOrCountry>CA</stateOrCountry>
      <signatureDate>05-15-2020</signatureDate>
    </signatureBlock>
    <summaryPage>
      <otherIncludedManagersCount>0</otherIncludedManagersCount>
      <tableEntryTotal>37</tableEntryTotal>
      <tableValueTotal>1194223</tableValueTotal>
      <isConfidentialOmitted>false</isConfidentialOmitted>
    </summaryPage>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>INFORMATION TABLE
<SEQUENCE>2
<FILENAME>Q12020XML.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns1:informationTable xmlns:ns1="http://www.sec.gov/edgar/document/thirteenf/informationtable">
	<ns1:infoTable>
		<ns1:nameOfIssuer>ABIOMED INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>003654100</ns1:cusip>
		<ns1:value>72978</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>502745</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>502745</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ACADIA PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>004225108</ns1:cusip>
		<ns1:value>68932</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1631524</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>1631524</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>AIMMUNE THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>00900T107</ns1:cusip>
		<ns1:value>47524</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>3295712</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>3295712</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ALDEYRA THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>01438T106</ns1:cusip>
		<ns1:value>182</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>73500</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>73500</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ALEXION PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>015351109</ns1:cusip>
		<ns1:value>57689</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>642491</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>642491</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ALIGN TECHNOLOGY INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>016255101</ns1:cusip>
		<ns1:value>13256</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>76205</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>76205</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ALIMERA SCIENCES INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>016259103</ns1:cusip>
		<ns1:value>804</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>200919</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>200919</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>AMAG PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>00163U106</ns1:cusip>
		<ns1:value>18557</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>3002748</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>3002748</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>AMICUS THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>03152W109</ns1:cusip>
		<ns1:value>68816</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>7447618</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>7447618</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>BIOMARIN PHARMACEUTICAL INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>09061G101</ns1:cusip>
		<ns1:value>130482</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1544163</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>1544163</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>CLOVIS ONCOLOGY INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>189464100</ns1:cusip>
		<ns1:value>29484</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>4635789</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>4635789</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>CYTOKINETICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>23282W605</ns1:cusip>
		<ns1:value>1458</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>123686</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>123686</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>DICERNA PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>253031108</ns1:cusip>
		<ns1:value>6095</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>331813</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>331813</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>EPIZYME INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>29428V104</ns1:cusip>
		<ns1:value>86108</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>5551803</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>5551803</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>IDERA PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>45168K405</ns1:cusip>
		<ns1:value>102</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>77044</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>77044</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>IMMUNOMEDICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>452907108</ns1:cusip>
		<ns1:value>71319</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>5290746</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>5290746</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>INSMED INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>457669307</ns1:cusip>
		<ns1:value>97072</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>6055623</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>6055623</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>INTRA-CELLULAR THERAPIES INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>46116X101</ns1:cusip>
		<ns1:value>575</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>37400</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>37400</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>KALEIDO BIOSCIENCES INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>483347100</ns1:cusip>
		<ns1:value>4846</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>787999</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>787999</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>KARYOPHARM THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>48576U106</ns1:cusip>
		<ns1:value>82601</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>4299901</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>4299901</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>MARINUS PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>56854Q101</ns1:cusip>
		<ns1:value>254</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>125321</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>125321</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>MINERVA NEUROSCIENCES INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>603380106</ns1:cusip>
		<ns1:value>219</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>36319</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>36319</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>MOMENTA PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>60877T100</ns1:cusip>
		<ns1:value>41560</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1527956</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>1527956</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>PROTHENA CORP PLC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>G72800108</ns1:cusip>
		<ns1:value>8296</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>775296</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>775296</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>PUMA BIOTECHNOLOGY INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>74587V107</ns1:cusip>
		<ns1:value>11784</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1396163</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>1396163</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>RETROPHIN INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>761299106</ns1:cusip>
		<ns1:value>686</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>47000</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>47000</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>REVANCE THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>761330109</ns1:cusip>
		<ns1:value>9112</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>615705</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>615705</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>RIGEL PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>766559603</ns1:cusip>
		<ns1:value>5526</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>3542551</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>3542551</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>SAGE THERAPEUTICS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>78667J108</ns1:cusip>
		<ns1:value>16849</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>586674</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>586674</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>STAAR SURGICAL CO</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>852312305</ns1:cusip>
		<ns1:value>105765</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>3278523</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>3278523</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>SUNESIS PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>867328700</ns1:cusip>
		<ns1:value>482</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>1162473</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>1162473</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>SYNDAX PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>87164F105</ns1:cusip>
		<ns1:value>725</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>66100</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>66100</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>UNITED THERAPEUTICS CORP</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>91307C102</ns1:cusip>
		<ns1:value>83121</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>876575</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>876575</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>UROGEN PHARMA LTD</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>M96088105</ns1:cusip>
		<ns1:value>437</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>24500</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>24500</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>VANDA PHARMACEUTICALS INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>921659108</ns1:cusip>
		<ns1:value>42837</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>4134846</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>4134846</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>WRIGHT MEDICAL GROUP NV</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>N96617118</ns1:cusip>
		<ns1:value>6960</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>242940</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>242940</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
	<ns1:infoTable>
		<ns1:nameOfIssuer>ZOGENIX INC</ns1:nameOfIssuer>
		<ns1:titleOfClass>COM</ns1:titleOfClass>
		<ns1:cusip>98978L204</ns1:cusip>
		<ns1:value>730</ns1:value>
		<ns1:shrsOrPrnAmt>
			<ns1:sshPrnamt>29500</ns1:sshPrnamt>
			<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
		</ns1:shrsOrPrnAmt>
		<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
		<ns1:otherManager>0</ns1:otherManager>
		<ns1:votingAuthority>
			<ns1:Sole>29500</ns1:Sole>
			<ns1:Shared>0</ns1:Shared>
			<ns1:None>0</ns1:None>
		</ns1:votingAuthority>
	</ns1:infoTable>
</ns1:informationTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
